A Phase 1, Randomised Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PRTX007 in Normal Healthy Volunteers
Latest Information Update: 28 Dec 2023
At a glance
- Drugs PRTX 007 (Primary)
- Indications Cancer; COVID 2019 infections; Hepatitis B; Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Primmune Therapeutics
- 14 Nov 2023 Results assessing safety of PRTX007 in healthy volunteers were presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 10 Nov 2023 Results published in the Media Release
- 10 Nov 2023 According to a Primmune Therapeutics media release, new clinical data were presented at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting).